Kazia Therapeutics Limited has announced new findings from an ex vivo study on the effects of paxalisib, its investigational PI3K-mTOR inhibitor, on metastatic burden in Stage IV HER2-positive metastatic breast cancer patients. The study demonstrated that paxalisib monotherapy achieved a complete disruption of circulating tumor cell clusters containing three or more cells. These results highlight paxalisib's potential to address metastatic progression in HER2-positive breast cancer, a subtype that accounts for 15-20% of cases and presents significant clinical challenges. Detailed datasets from this study have been submitted for presentation at an upcoming global oncology meeting in 2025.